奈玛特韦/利托那韦与安慰剂对照预防成人急性COVID-19后长新冠的随机试验:PanoramicNOR试验
PanoramicNOR试验是一项随机双盲安慰剂对照试验,计划招募2000名18至64岁急性COVID-19患者,随机接受5天奈玛特韦/利托那韦(Paxlovid®)或安慰剂治疗,主要终点为3个月随访时长新冠症状(疲劳、呼吸困难、认知症状)的持续存在,并在6、12、24个月再评估。
要点
- 试验评估5天口服奈玛特韦/利托那韦能否预防急性COVID-19后长新冠。
- 纳入18至64岁非妊娠、症状不超过5天且PCR和/或抗原检测阳性的急性COVID-19患者。
- 主要终点为3个月随访时疲劳、呼吸困难、认知症状中至少一项持续存在的比例。
核心结论
- 试验旨在评估急性COVID-19期间使用奈玛特韦/利托那韦能否预防长新冠。
研究设计与样本
- 随机双盲安慰剂对照试验,计划招募2000名18至64岁非妊娠急性COVID-19患者,PCR和/或抗原检测阳性且症状持续时间不超过5天。
- 参与者按1:1随机接受5天疗程Paxlovid(两片150毫克奈玛特韦和一片100毫克利托那韦,每日两次)或5天疗程安慰剂(片数相同、外观相同)。
主要发现
- 主要终点为符合长新冠的持续症状,以二分变量评估:以下症状中一项或多项存在(1)或不存在(0):(i)疲劳,(ii)呼吸困难,(iii)认知症状(记忆和/或注意力问题)。
- 主要结局在3个月随访时评估,随后在6、12和24个月重新评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The high prevalence of long-term persisting symptoms after COVID-19 (coronavirus disease 2019), termed long COVID or post-COVID-19 condition, even among those with mild initial disease, may have a large public health impact. Apart from avoiding infection, there is no proven prevention or treatment for long COVID. We will perform a randomized placebo-controlled clinical trial to assess whether treatment with the novel antiviral, nirmatrelvir and ritonavir (Paxlovid®) for acute COVID-19 can prevent the development of long COVID. METHODS: This is a randomized double-blinded placebo-controlled trial that aims to recruit 2000 nonpregnant persons aged 18 to 64 years with acute COVID-19 with positive PCR and/or antigen test and symptom duration of not more than 5 days. Participants will be randomized 1:1 to a 5-day course of Paxlovid (two tablets 150-mg nirmatrelvir and one tablet 100-mg ritonavir twice daily) or a 5-day course of placebo (similar number of tablets of equal appearance). The primary endpoint will be persistent symptoms compatible with long COVID, assessed as the prevalence of a dichotomous variable corresponding to the presence (1) or absence (0) of one or more of the following symptoms: (i) fatigue, (ii) dyspnea, and (iii) cognitive symptoms (memory and/or concentration problems). The primary outcome will be evaluated at 3-month follow-up and then re-evaluated at 6, 12, and 24 months. DISCUSSION: As more than 750 million people with confirmed COVID-19 have survived globally, the potential burden of long COVID on societies is formidable. If a simple 5-day oral treatment course with nirmatrelvir/ritonavir is shown to prevent long COVID, it would be a highly attractive intervention at an individual level and a mitigation of its public health consequences. TRIAL REGISTRATION: ClinicalTrials.gov NCT05852873. Registered on May 2023.
引用
- Blomberg B, Myklebust NN, Oppegaard O, et al. Randomized trial of nirmatrelvir/ritonavir versus placebo for adults with acute COVID-19 to prevent long COVID: PanoramicNOR Trial. Trials. 2025. PMID: 41199272. doi:10.1186/s13063-025-09226-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。